Abstract
Any pharmaceutical company willing to invest heavily in osteoarthritis (OA) R&D has a good chance of identifying a disease modifying agent that will revolutionise OA therapy. This optimism was expressed at the 18th Meeting of the International League Against Rheumatism (ILAR), held earlier this month in Barcelona, Spain. It results from the increased understanding of how OA causes cartilage breakdown.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
